Biosolution Designs is changing the paradigm.
An Invention BioStudio
BSD is an intellectual property holding company developing complex DNA-encoded technologies for multigenic biotechnology applications.
Leadership
Who is BSD?
Dr. Thomas Reed
Founder & Chief executive officer
25+ years of synthetic biology, cardiovascular disease, and technology invention expertise.
Former founder & CSO of Intrexon (now Precigen) and President of TRIPLE-GENE.
Leader and inventor for 25+ biotechnology and DNA engineering platforms.
Sam Glickstein
Chief Operations Officer
10+ years of entrepreneurship, operational, and business development leadership.
Former founder & CEO of Biotrophics, an innovative insect genetic engineering company.
Leader and founder of several agtech and biotech companies.
Shruti Abbato
Chief Development Officer
25+ years of biotechnology business development and strategy expertise.
Chief business executive at SalioGen and MaxCyte, gene & cell therapy companies.
Deals and strategy advisor to multiple Series A stage companies.
BSD forms new focused independent entities to scale applications of its inventions.
the First gene-and-cell therapy-centric biotools company
Tools & Services
Commercializing and popularizing across the industry each multigenic platform as biotools for research use, including our breakthrough Bird of Prey platform. Offering DIY tools and vector building services
BSD’s Multigenic Delivery Systems company
Platforms & Therapuetics
Founded in 2024, MULTIGENIX is building a platform capability for integrated genetic control, genome engineering and transgene delivery of large genetic cargo therapies. This unified approach aims to tackle complex diseases which are currently “undruggable” by traditional genetic medicines.